Transaction · 0001193125-26-377309

Kenney Christopher John

KENNEY CHRISTOPHER JOHN, CMO, reported an open-market or private sale at Xenon Pharmaceuticals Inc. involving 6368.000000 shares for an estimated $383145.37. Reported holdings after the transaction were 702.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
XENEXenon Pharmaceuticals Inc.
Trade date
Aug 28, 2026
Filing date
Sep 01, 2026
View on SEC Insider profile
Estimated value-$383kShares × reported price
Shares traded6.36k$60.17 per share
Holdings after702Direct
% of reported position traded90.07%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 7,070 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

XENE price since this filing

Daily closing prices, with the filing date and available return windows
XENE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.2%1w ago +1.3%1d ago +1.2%
Returns since7d -0.8%30d -38.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-377309
Common Shares
Transaction date
Aug 28, 2026
Filed Sep 01, 2026, 01:59 AM · 4d delay
Shares
6,368 sh
$60.17 per share
Estimated value
-$383k
Computed from shares × price
Holdings after
702 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Reduction 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.

  2. F2

    The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multi…

  3. F3

    The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multi…

  4. F4

    The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on upd…

Original filing · 0001193125-26-377309
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

XENE